627525-89-7

Basic information

• Product Name: 2-(3-(difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(3-(difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS NO: 627525-89-7
• Molecular Formula: C13H17BF2O2
• Molecular Weight: 254.0806864
• Mol File: 627525-89-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 313.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.09±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 2-(3-(difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-(difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(627525-89-7)
• EPA Substance Registry System: 2-(3-(difluoromethyl)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(627525-89-7)

Safety Data

• Hazardous Substances Data: 627525-89-7(Hazardous Substances Data)

Usage

Class

dioxaborolane derivative

Structural components

difluoromethylphenyl group, four methyl groups attached to the boron atom

Usage

in chemical reactions and organic synthesis processes due to its unique structure and reactivity

Potential applications

development of pharmaceuticals, agrochemicals, and materials science

Importance

boron-containing structure makes it a candidate for cross-coupling reactions and as a building block for the synthesis of complex organic molecules.

Upstream product

• 29848-59-7 1-bromo-3-difluoromethyl-benzene 
• 73183-34-3 bis(pinacol)diborane 
• 325142-82-3 4,4,5,5-tetramethyl-2-(3-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane 

Relevant articles and documents

Arenethiolate as a Dual Function Catalyst for Photocatalytic Defluoroalkylation and Hydrodefluorination of Trifluoromethyls

Thiol is known to act as a hydrogen atom transfer catalyst working in synergy with a photocatalyst in photoredox catalysis, but we report herein that an arene thiolate with an appropriate substituent can be photoactivated under visible light to function as both a strongly reducing electron-donating redox catalyst and a HAT catalyst to enable catalytic C-F activation of trifluoromethyl substrates for selective hydrodefluorination and coupling with various alkenes in the presence of formate salts. These reactions demonstrate the promising utility of arenethiolates as dual function photocatalysts. The synthetic utility of this method is demonstrated by the broad scope of amenable trifluoromethyl substrates, including trifluoromethylated (hetero)arenes, trifluoroacetates, and trifluoroacetamides, which exhibited high levels of chemoselectivity. The reaction efficacy allows site-selective late-stage functionalization of multitrifluoromethylated bioactive compounds and pharmaceuticals.

SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110 activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.